Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
Go back to Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer| JAZZ PHARMACEUTICAL (NASDAQ: JAZZ) | Delayed: 244.54 -6.56 (2.61%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $251.10 | 52 Week High | $160.00 | |||
| Open | $249.48 | 52 Week Low | $95.80 | |||
| Day High | $250.64 | P/E | 45.45 | |||
| Day Low | $244.49 | EPS | $5.38 | |||
| Volume | 1,207,552 | |||||
